Mr Adam Odojewski > Dentons > Warsaw, Poland > Lawyer Profile

Dentons
UL. ZAJECZA 4
00-351 WARSZAWA
POLAND
Poland

Work Department

Life Sciences and Healthcare; Dispute Resolution

Position

Adam Odojewski, counsel, is head of the Life Sciences and Health Care team in Dentons in Poland. He is also a member of the Dispute Resolution practice group.

He specialises in pharmaceutical law and laws governing medicinal products, with a focus on regulations concerning reimbursement and state financing of healthcare services, including contracts with the National Health Fund. He has been involved in the comprehensive preparation of pharmaceutical companies for compliance with the major reimbursement law reform that came into force in Poland in 2012. He was the lead lawyer representing major pharmacy chains in Poland in a massive dispute with pharmaceutical authorities attempting to revoke pharmacy licences under the so-called “pharmacy for pharmacists” law, which came into force in 2017. Between 2020 and 2023, Adam successfully defended more than 30 branded pharmacies in prime locations in Poland from forced liquidation.

Adam’s practice also focuses on civil and commercial law. He is actively involved in representing clients in litigation, including product liability, advertising law, unfair competition law and personal rights protection law. He is also experienced in obtaining interim injunctions.

Career

  • Counsel at Dentons since 2021
  • With Dentons since 2013
  • Consultant / Senior Consultant at PwC, 2009–2012
  • Admitted to the Polish bar (2016)

Languages

Polish, English

Education

  • University of Warsaw, 2011, Master of Laws
  • University of Warsaw, 2010, Master of Finance and Banking

Lawyer Rankings

Poland > Healthcare and life sciences

(Rising stars)

Adam OdojewskiDentons

Praised for its ‘exceptional‘ industry knowledge, the team at Dentons regularly assists clients with the acquisition of wholesale and pharmacy trade licenses, as well as handling disputes concerning the withdrawal of licences. Adam Odojewski leads the team, and is noted for his deep knowledge of licensing issues within the pharmaceutical industry, and his regulatory expertise in the laws governing medicinal products and medical devices.